Babu™ has closed its first round of funding for 2021. We are opening the second round of investing in 2021/22 and we are ready to support many more fascinating, ground-breaking, and revolutionary scientific projects standing on our Three Pillars. Become a Babu™  - change!

Internal Project - Therapeutic & Prophylactic Drug for Covid-19

Babu™ presents its first internal Project dedicated to Covid-19. It is a novel treatment method based on small nucleic molecules targeting the selected SARS-CoV2 region on its surface. Designed by Babu's™ founder, Steve Liebich, and executed by Babu's™ subsidiary, Babu One Therapeutics Inc., Babu-One™ opens the door to a new niche aiming not only Covid-19 but other droplet-transmitted viral disorders as well. With Babu-One™ has the real chance to help the entire world during one of its darkest times. ​

Partnership with KBHB to fight epidermolysis bullosa (EB)

KBHB is an early start-up company from Germany focused on developing a unique and novel genetic and metabolic disorders platform. By exploiting ribosomal machinery editing tools, they push the boundaries of current molecular biology fields, including molecular editing and target-specific proteomics. The "hijacking of ribosomes" method seems to be too good to be true and yet its early experimental results indicate that Babu™ has been right again. EB occurs in about half a million people on the planet, with extremely high mortality rate, and its two most abundant symptoms: skin fragility and mechanically-induced blistering make it almost unbearable for every affected patient. There is no treatment as of now. KBHB may change this game - not only for EB, but for many other incurable disorders.

Partnership with RockFish to fight chronic kidney disease

RockFish Bio is an Austrian high-biotech company focused on pharmacological treatment against senescent cells accumulating in the aging organs, and thus leading to their damage. RockFish's senolytic approach is unique and extraordinarily efficient, which stands as another complex yet simple treatment platform for age-related disorders. RockFish has a solid expertise in tackling Chronic Kidney Disease (CKD), which has become their model disease, and an important one too! Approximately 10% of the global population suffers from CKD with total costs exceeding $100B. But here we are - we can cure it once and for all!

Partnership with The Walking Egg Program to fight infertility and to prevent sexually-transmitted diseases

The Walking Egg is a non-profit organization from Belgium founded in 2010 "by scientists and an artist. From this unusual blend, a unique objective came forth: to implement accessible infertility programs in resource-poor countries." This unique blend not only generates better results in treating infertility with simplified techniques of diagnostics, culture systems for clinical IVF, and low-cost ovarian stimulation protocols, but also studies and supports the sociocultural aspects of childlessness on a global scale and advocates for extensive sexual education in underdeveloped countries. Instead of spending thousands of dollars per infertility therapy, why not $1,000? Instead of treating sexually transmitted diseases, why not to prevent them?

Partnership with American Gene Technologies (AGT) To Develop Revolutionary Gene Therapy Platform

Gene therapy is on the verge of revolutionizing the entire health care system. Efficiently developed, optimized, and individualized gene therapy can cure all monogenic diseases and many more. AGT (www.americangene.com) delivers the IP portfolio valued to $2.4 billion and having mastered their own lentivirus vector (LentiVector™) system, AGT has all necessary tools to address over 1000 incurable diseases, including their phenomenal immuno-oncology (I/O) program for HIV infection and highly efficient liver cancer. The first clinical trials for HIV will begin in 2020 and the I/O program for hepatocellular carcinoma human trials should be ready in early to mid-2021! This is pure science and imagination of tomorrow. However, we start today. 

Supporting Telocyte In Fighting Alzheimer's Disease

Over 44 million people are affected by Alzheimer’s disease. Those afflicted suffer significant memory loss, speech and writing progressive aberration, and dysfunctional problem solving. Statistically, one in three seniors dies with Alzheimer’s or another type of dementia.
This makes the disease the 6th leading cause of death in the United States. Today we are proud to announce Babu™ intends to collaborate with Telocyte LLC (www.telocyte.com) as they prepare to take their telomerase gene therapy treatment for Alzheimer’s Disease into first human clinical trials with the FDA. This will only be their first step, as they progress on many age related diseases which can also be addressed. Together we will hold the key for the man’s longevity.

Project Submission Guidelines

Read our Project Submission General Guidelines to prepare yourself for submitting your ground-breaking research project to  Babu™. Once we open the submission window for individual researchers and organizations, you will be ready and prepared. We cannot wait to build the new world with you!